Effect of preoperative transcatheter arterial chemoembolization on angiogenesis of hepatocellular carcinoma cells

Table 1 Expression of VEGF protein in groups A, B, C, D, and the non-TACE group

Group	Cases	Expression of VEGF (%)
		-	+	++	+++
A	11	2 (18.2)	4 (36.4)	3 (27.3)	2 (18.2)
B	33	5 (15.2)	6 (18.2)	9 (27.3)	13 (39.4)
C	23	2 (8.7)	6 (26.1)	4 (17.4)	11 (47.8)
D	12	1 (8.3)	2 (16.7)	4 (33.3)	5 (41.7)
Non-TACE group	57	17 (29.8)	16 (28.1)	13 (22.8)	11 (19.3)

Table 2 Correlation between expression of CD31 and VEGF protein

Group	Cases	MVD
VEGF (-)	27	35.47 ± 17.35
VEGF (+)	34	44.12 ± 15.84
VEGF (++)	33	52.56 ± 17.29
VEGF (+++)	42	60.72 ± 23.46

Table 3 Correlation between courses of TACE and expression of VEGF protein

Group	Cases	Expression of VEGF (%)
		-	+	++	+++
One-course	50	5 (10.0)	14 (28.0)	12 (24.0)	19 (38.0)
Two-course	19	3 (15.8)	4 (21.1)	3 (15.8)	9 (47.4)
Three-, four- or five-course	10	2 (20.0)	0 (0.0)	5 (50.0)	3 (30.0)
Non-TACE group	57	17 (29.8)	16 (28.1)	13 (22.8)	11 (19.3)

Table 4 Correlation between interval of TACE and expression of VEGF protein

Group	Cases	Expression of VEGF (%)
		-	+	++	+++
1 mo interval	27	4 (14.8)	7 (25.9)	7 (25.9)	9 (33.3)
1-2 mo interval	28	2 (7.1)	7 (25.0)	6 (21.4)	13 (46.4)
2-3 mo interval	16	3 (18.8)	2 (12.5)	5 (31.3)	6 (37.5)
> 3 mo interval	8	1 (12.5)	2 (25.0)	2 (25.0)	3 (37.5)
Non-TACE group	57	17 (29.8)	16 (28.1)	13 (22.8)	11 (19.3)